메디메스터

비상장계속사업자

MEDIMASTER CO., LTD

강성준

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

메디메스터

Business Reg. No. 2208655291 · CEO 강성준

I.Investment Overview

Target메디메스터 (2208655291)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명메디메스터
영문명MEDIMASTER CO., LTD
대표자강성준
사업자등록번호2208655291
법인등록번호1101112688351
설립일2003.01.07
종업원수19명

V.Workforce

19

Current headcount · 2026.06 as of

VI.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW173.72021178.42022186.42023162.820241452025
영업이익100M KRW17202112202212.820231.820241.72025
순이익100M KRW13.520219.7202211.22023120240.62025
Item20252024202320222021
자산총계169.8억원151.7억원157.3억원161.3억원185.1억원
부채총계155.2억원109.7억원108.3억원113.5억원137.1억원
자본총계14.6억원42억원49억원47.8억원48억원
매출액145억원162.8억원186.4억원178.4억원173.7억원
영업이익1.7억원1.8억원12.8억원12억원17억원
순이익5,985만원1억원11.2억원9.7억원13.5억원

VII.Financial Ratios

FY2025 basis

1.2%

영업이익률

0.41%

순이익률

0.35%

ROA

4.09%

ROE

1,060.5%

부채비율

8.62%

자기자본비율

VIII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

메디메스터 투심보고서 | Alpha Lenz